GoldenGolden
Advanced Search
QurAlis

QurAlis

QurAlis is a biotechnology company developing treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

May 13, 2020
QurAlis officially launches under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD).

May 13, 2020
QurAlis raises a $42,000,000 series A round.
November 19, 2018
QurAlis raises a $5,500,000 seed round from BioInnovation Capital.
November 2018
QurAlis raises a $5,500,000 seed round from Amgen Ventures, BioInnovation Capital and MP Healthcare Venture Management.

Funding rounds

SBA Awards

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

QurAlis Raises $5.5 Million Seed Round

BusinessWire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Viva Biotech Holdings
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- March 2nd-6th, 2021, Viva Biotech successfully hosted the 2021 Partnership Summit. Over 300 attendees joined the Summit, including...
Ben Adams
July 1, 2020
FierceBiotech
In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
Ben Adams
May 13, 2020
FierceBiotech
QurAlis has officially launched under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis and genetically related frontotemporal dementia.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.